5 Most Promising Penny Stocks According to Wall Street Analysts

4. MannKind Corporation (NASDAQ:MNKD)

Average Upside Potential: 104.08%

MannKind Corporation (NASDAQ:MNKD) is one of the most promising penny stocks according to Wall Street analysts. On June 3, MannKind reached key milestones in its clinical program for nintedanib DPI, a dry powder inhalation therapy for idiopathic pulmonary fibrosis/IPF. The company has completed patient randomization for its US Phase 1b INFLO-1 trial and successfully enrolled the first participant in its global Phase 2 INFLO-2 study. Data from the INFLO-1 trial is expected in Q3 2026.

The nintedanib DPI program utilizes MannKind’s proprietary Technosphere technology to deliver medication directly to the lungs. By targeting the site of the disease, the company aims to maintain antifibrotic efficacy while minimizing the systemic side effects often associated with the currently approved oral form of nintedanib. This approach is designed to improve treatment tolerability, long-term adherence, and the potential for combination therapies in patients with IPF.

The Phase 2 INFLO-2 trial is a randomized, double-blind study designed to evaluate the safety, tolerability, and optimal dosing of nintedanib DPI in ~210 participants across 85 global sites. Following a 12-week treatment period, the study includes a 24-week open-label extension to assess secondary efficacy endpoints, including lung function and patient-reported outcomes, further defining the therapy’s potential as a new standard of care for the condition.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapeutic products and devices for those living with endocrine and orphan lung diseases.